BiotechTubeBiotechTube
Home/BioMarin Pharmaceutical/Marni Kottle
MK

Marni Kottle

Executive Vice President, Chief Corporate Affairs Officer

BioMarin Pharmaceutical

Therapeutic Areas

Rare Genetic DiseasesLysosomal Storage DiseasesEnzyme Replacement TherapyGene TherapyMucopolysaccharidosisAchondroplasiaHemophiliaPhenylketonuriaMetabolic Disorders

BioMarin Pharmaceutical Pipeline

DrugIndicationPhase
VOXZOGO (vosoritide)AchondroplasiaCommercial
PALYNZIQ (pegvaliase-pqpz)Phenylketonuria (PKU)Commercial
Enzyme Replacement TherapyMucopolysaccharidosis ICommercial
Gene TherapyHemophilia ACommercial
Metabolic TherapyRare Metabolic ConditionCommercial
ENPP1 deficiency programENPP1 deficiency/GACIClinical

Leadership Team at BioMarin Pharmaceutical

AH
Alexander Hardy
President and Chief Executive Officer
BR
Brian R. Mueller
Executive Vice President, Chief Financial Officer
GF
Greg Friberg
Executive Vice President, Chief Research & Development Officer
CH
Cristin Hubbard
Executive Vice President, Chief Commercial Officer
JS
James Sabry
Executive Vice President, Chief Business Officer
CG
C. Greg Guyer
Executive Vice President, Chief Technical Officer
GE
G. Eric Davis
Executive Vice President, Chief Legal Officer
AW
Amy Wireman
Executive Vice President, Chief People Officer
AD
Arpit Davé
Executive Vice President, Chief Digital and Information Officer
RA
Richard A. Meier
Board of Directors
View full BioMarin Pharmaceutical profile